Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.49 |
| ▸ | CA2 | P00918 | 4/20 | 0.49 |
| ▸ | CA12 | O43570 | 2/20 | 0.49 |
| ▸ | CA9 | Q16790 | 2/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | JAK3 | P52333 | 3/20 | 0.41 |
| ▸ | JAK2 | O60674 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12849107 | 1.00 | CA1 (0.49) | CA1CA2CA12CA9EPHX2 | |
| SCHEMBL13064015 | 1.00 | CA1 (0.49) | CA1CA2CA12CA9EPHX2 | |
| SCHEMBL12225565 | 0.88 | EPHX2 (0.50) | EPHX2EPHX1 | |
| SCHEMBL961566 | 0.88 | EPHX2 (0.50) | EPHX2EPHX1 | |
| SCHEMBL12820400 | 0.88 | EPHX2 (0.50) | EPHX2EPHX1 | |
| SCHEMBL28206408 | 0.86 | CA1 (0.46) | CA1CA2CA12CA9EPHX2 | |
| SCHEMBL3535134 | 0.85 | CA1 (0.45) | CA1CA2CA12CA9EPHX2 | |
| SCHEMBL2030025 | 0.85 | CA1 (0.45) | CA1CA2CA12CA9EPHX2 | |
| SCHEMBL3088177 | 0.85 | CA1 (0.45) | CA1CA2CA12CA9EPHX2 | |
| SCHEMBL23110169 | 0.83 | CA1 (0.44) | CA1CA2CA12CA9EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11731981-B2 | CCR2 receptor antagonists and uses thereof | CENTREXION THERAPEUTICS CORPORATION (US) | 2023-08-22 | — | — | US | disclosed |
| WO-2023006097-A1 | BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUND AND USE THEREOF AS ANDROGEN RECEPTOR DEGRADER | 海创药业股份有限公司 | 2023-02-02 | — | — | WO | disclosed |
| WO-2022133064-A1 | FUSED PYRIMIDINE COMPOUNDS AS INHIBITORS OF MENIN-MLL INTERACTION | BIOMEA FUSION, INC. (US) | 2022-06-23 | — | — | WO | disclosed |
| US-20220002310-A1 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | ANKURA TRUST COMPANY, LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT | 2022-01-06 | — | — | US | disclosed |
| WO-2021262596-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION | PMV PHARMACEUTICALS, INC. (US) | 2021-12-30 | — | — | WO | disclosed |
| WO-2021242923-A1 | TLR2 MODULATOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | AXIAL THERAPEUTICS, INC. (US) | 2021-12-02 | — | — | WO | disclosed |
| EP-2814828-B9 | PERIPHERALLY RESTRICTED DIPHENYL PURINE DERIVATIVES | RES TRIANGLE INST (US) | 2020-10-07 | — | — | EP | disclosed |
| EP-3336090-B1 | IRAK4 INHIBITOR AND USE THEREOF | BEIJING HANMI PHARMACEUTICAL CO LTD (CN) | 2020-07-22 | — | — | EP | disclosed |
| EP-3294732-B1 | BENZIMIDAZOLE AND IMADAZOPYRIDINE CARBOXIMIDAMIDE COMPOUNDS HAVING ACTIVITY AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | GILEAD SCIENCES INC (US) | 2019-09-25 | — | — | EP | disclosed |
| US-20170362249-A1 | NEW CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | ANKURA TRUST COMPANY, LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT | 2017-12-21 | — | — | US | disclosed |
| WO-2006094063-A1 | QUINOLINONE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE, INC. (US) | 2006-09-08 | — | — | WO | disclosed |
| US-20060199839-A1 | Quinolinone compounds as 5-HT4 receptor agonists | THERAVANCE, INC. | 2006-09-07 | — | — | US | disclosed |
| WO-2006069125-A1 | INDAZOLE-CARBOXAMIDE COMPOUNDS | THERAVANCE, INC. (US) | 2006-06-29 | — | — | WO | disclosed |
| US-20060135764-A1 | Indazole-carboxamide compounds | THERAVANCE, INC. | 2006-06-22 | — | — | US | disclosed |
| WO-2006052889-A2 | QUINOLINONE-CARBOXAMIDE COMPOUNDS | THERAVANCE, INC. (US) | 2006-05-18 | — | — | WO | disclosed |
| WO-2006052640-A1 | 5-HT4 RECEPTOR AGONIST COMPOUNDS | THERAVANCE, INC. (US) | 2006-05-18 | — | — | WO | disclosed |
| US-20060100236-A1 | For therapy of disorder of reduced motility of gastrointestinal tract, chronic constipation, functional dyspepsia, delayed gastric emptying, gastroesophageal reflux disease, gastroparesis, diabetic and iodiopathic gastropathy, post-operative ileus, intestinal pseudo-obstruction, irritable bowel syndrome | THERAVANCE, INC. (US) | 2006-05-11 | — | — | US | disclosed |
| US-20060100426-A1 | Quinolinone-carboxamide compounds | THERAVANCE, INC. | 2006-05-11 | — | — | US | disclosed |
| US-20050197335-A1 | 1-isopropyl-1H-indazole-3-carboxylic acid {(1S,3R,5R)-8-[2-(4-acetylpiperazin-1-yl)-ethyl]8-azabicyclo[3.2.1]oct-3-yl}amide; improved pharmacokinetic, bioavailability; gastrointestinal disorders: irritable bowel syndrome (IBS), chronic constipation, dyspepsia; CNS behavioral, mood disorder | THERAVANCE BIOPHARMA R&D IP, LLC | 2005-09-08 | — | — | US | disclosed |
| WO-2005080389-A1 | INDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE, INC. (US) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199839-A1 | Quinolinone compounds as 5-HT4 receptor agonists | HTR4, HTR5A, HTR1A | CA1 4697/4885CA2 4365/4885CA12 4869/4885 |
| US-20050197335-A1 | 1-isopropyl-1H-indazole-3-carboxylic acid {(1S,3R,5R)-8-[2-(4-acetylpiperazin-1-yl)-ethyl]8-azabicyclo[3.2.1]oct-3-yl}amide; improved pharmacokinetic, bioavailability; gastrointestinal disorders: irritable bowel syndrome (IBS), chronic constipation, dyspepsia; CNS behavioral, mood disorder | HTR4, HTR5A, HTR3C | CA1 4643/4885CA2 4487/4885CA12 4656/4885 |
| US-11731981-B2 | CCR2 receptor antagonists and uses thereof | CCR2, CCRL2, CCR1 | CA1 3738/4885CA2 868/4885CA12 2163/4885 |
| US-20060135764-A1 | Indazole-carboxamide compounds | HTR4, HTR5A, HTR3B | CA1 4252/4885CA2 3377/4885CA12 4781/4885 |
| US-20060100236-A1 | For therapy of disorder of reduced motility of gastrointestinal tract, chronic constipation, functional dyspepsia, delayed gastric emptying, gastroesophageal reflux disease, gastroparesis, diabetic and iodiopathic gastropathy, post-operative ileus, intestinal pseudo-obstruction, irritable bowel syndrome | GIPR, GPR4, GPR119 | CA1 4109/4885CA2 1906/4885CA12 3423/4885 |
| US-20170362249-A1 | NEW CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | CCR2, CCRL2, CCR1 | CA1 3659/4885CA2 887/4885CA12 2191/4885 |
| US-20220002310-A1 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | CCR2, CCRL2, CCR1 | CA1 3738/4885CA2 868/4885CA12 2163/4885 |
| US-20060100426-A1 | Quinolinone-carboxamide compounds | HTR4, HTR5A, HTR2C | CA1 3912/4885CA2 2979/4885CA12 4611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.